Thank You!
Our Fall fundraiser raised $125,000 for research and patient support initiatives. With your help, we will continue to press forward in our search for a cure.

If you haven't made a contribution yet, it's not too late.
Stay Informed: Recent Advances in Treatment
To start off the new year, we partnered again with CancerCare to present a January 9th educational webinar, Gastric Cancer: Treatment Advances. If you missed it, the recorded webcast is available online. Listen or watch at the link below.
Chef Hans Rueffert welcomes back registered dietitian, Dr. Ellen Steinberg to discuss ways to meet your needs when eating at fast food restaurants. Most importantly, remember to advocate for your body’s new digestive reality. Don’t be shy about customizing an order to help you most successfully fuel your body until your next meal.
Share Your Voice and Experience
The Center for Information and Study on Clinical Research Participation (CISCRP) is an independent non-profit organization, dedicated to including the voice of patients and care partners in the clinical research process. They regularly engage with affected individuals and families to include the community voice in research endeavors.

CISCRP, together with a pharmaceutical company, is planning to conduct a virtual focus group in late February/early March among individuals diagnosed with gastric (stomach) cancer and their care partners. The goal of the focus group is to learn from patients how to ensure treatments for gastric cancer best meet the unique needs of individuals with this condition and their families.

The virtual focus group will provide an opportunity for those affected by gastric cancer to share their experiences living with/caring for this condition, experiences with treatment and views on what they would like an ideal treatment to address, what outcomes would be most meaningful, as well as share thoughts on clinical research and clinical trials for this condition. 
To check eligibility and information about participation, click below:
Research Roundup
Novel medicines and treatment regimens for gastric cancer are showing promise, new research reveals.

A novel combination of chemotherapy, immunotherapy and a VEGFR-2 tyrosine kinase inhibitor resulted in median overall survival of more than a year in patients with previously treated, inoperable gastric cancer. Overall tolerance of the treatment was favorable, the researchers reported.

The oral chemo combination trifluridine and tipiracil (FTD/TPI) was proven to provide a clinical benefit in patients with metastatic gastric cancer, including improved survival, according to a study published in ESMO Open.

A trial of a novel bispecific innate cell engager (ICE) called AFM24 combined with the immunotherapy drug Tecentriq had a tolerable safety profile and favorable responses in patients with advanced EGFR-expressing solid tumors, including gastric cancer, a team of Spanish researchers reported.
Quick Links to Resources
Special Thanks to Our
National Sustaining Sponsors
Spread the word. Share the Gastric Cancer Foundation Newsletter.